会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • INDOLES AND THEIR THERAPEUTIC USE
    • 吲哚及其治疗用途
    • WO2009077728A1
    • 2009-06-25
    • PCT/GB2008/004107
    • 2008-12-12
    • ARGENTA DISCOVERY LIMITEDHYND, GeorgeMONTANA, John, GaryFINCH, HarryARIENZO, RosaAVITABILE-WOO, BarbaraDOMOSTOJ, Mathias
    • HYND, GeorgeMONTANA, John, GaryFINCH, HarryARIENZO, RosaAVITABILE-WOO, BarbaraDOMOSTOJ, Mathias
    • C07D209/04C07D401/06C07D403/06C07D403/12C07D409/06C07D409/14C07D417/06A61K31/404
    • C07D209/12C07D209/04C07D401/06C07D403/06C07D403/12C07D409/06C07D409/14C07D417/06C07D417/14
    • Compound of formula (I) are are ligands of the CRTH2 receptor, useful inter alia for treatment of inflammatory conditions. Wherein X is -SO 2 - or *-SO 2 NR 3 - wherein the bond marked with an asterisk is attached to Ar 1 ; R 1 is hydrogen, fluoro, chloro, CN or CF 3 ; R 2 is hydrogen, fluoro or chloro; R 3 is hydrogen, C 1 C 8 alkyl or C 3 -C 7 cycloalkyl; Ar 1 is phenyl or a 5- or 6-membered heteroaryl group selected from furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C 3 - C 7 cycloalkyl, -O(C 1 -C 4 alkyl) or C 1 C 6 alkyl, the latter two groups being optionally substituted by one or more fluoro atoms; and Ar 2 is phenyl or 5- or 6-membered heteroaryl group selected from pyrrolyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C 3 - C 3 - C 7 cycloalkyl, -O(C 1 -C 4 alkyl) or C 1 C 6 alkyl, the latter two groups being optionally substituted by one or more fluoro atoms.
    • 式(I)的化合物是CRTH2受体的配体,特别用于治疗炎性病症。 其中X是-SO 2 - 或* -SO 2 NR 3 - ,其中用星号附着的键连接到Ar1上; R1是氢,氟,氯,CN或CF3; R2是氢,氟或氯; R3是氢,C1C8烷基或C3-C7环烷基; Ar 1是苯基或选自呋喃基,噻吩基,恶唑基,噻唑基,咪唑基,吡唑基,异恶唑基,异噻唑基,吡啶基,哒嗪基,嘧啶基和吡嗪基的5-或6-元杂芳基,其中苯基或杂芳基任选被一个 或更多个独立地选自氟,氯,CN,C 3 -C 7环烷基,-O(C 1 -C 4烷基)或C 1 -C 6烷基的取代基,后两个基团任选被一个或多个氟原子取代; 并且Ar 2是苯基或选自吡咯基,呋喃基,噻吩基,恶唑基,噻唑基,咪唑基,吡唑基,异恶唑基,异噻唑基,吡啶基,哒嗪基,嘧啶基和吡嗪基中的5-或6-元杂芳基,其中苯基或杂芳基任选被取代 通过一个或多个独立地选自氟,氯,CN,C 3 -C 3 -C 7环烷基,-O(C 1 -C 4烷基)或C 1 -C 6烷基的取代基,后两个基团任选被一个或多个氟原子取代。
    • 6. 发明申请
    • INDOLE DERIVATIVES AS LIGANDS OF CRTH2 RECEPTORS
    • 作为CRTH2受体配体的衍生物
    • WO2010142934A1
    • 2010-12-16
    • PCT/GB2009/050671
    • 2009-06-12
    • PULMAGEN THERAPEUTICS (ASTHMA) LIMITEDHYND, GeorgeMONTANA, John GaryFINCH, HarryARIENZO, RosaAHMED, Shahadat
    • HYND, GeorgeMONTANA, John GaryFINCH, HarryARIENZO, RosaAHMED, Shahadat
    • C07D209/10C07D401/06C07D401/12C07D401/14C07D403/06A61P37/00A61K31/4439C07D409/06C07D409/14C07D413/06C07D417/06C07D417/14A61K31/4178A61K31/422A61K31/404
    • C07D417/14C07D209/10C07D401/06C07D401/12C07D401/14C07D403/06C07D409/06C07D413/06C07D417/06
    • The following compounds are CRTH2 antagonists, useful in treatment of respiratory disease: {3-[3-chloro-4-(pyridine-2-sulfonyl)isothiazol-5-ylmethyl]-5-fluoro-2- methylindol-1-yl}acetic acid, [3-(5-benzenesulfonyl-3-methyl-3H-imidazol-4-ylmethyl)-5-fluoro-2- methylindol-1-yl]acetic acid, [3-(5-benzenesulfonyloxazol-4-ylmethyl)-5-fluoro-2-methylindol-1-yl]acetic acid, [3-(3-benzenesulfonyl-4-met ylthiophen-2-ylmethyl)-5-fluoro-2-methylindol-1- yl]acetic acid, {5-fluoro-2-methyl-3-[2-(pyridin-2-ylsulfamoyl)benzyl]indol-1-yl}acetic acid, {5-fluoro-2-methyl-3-[4-methyl-3-(pyridine-2-sulfonyl)thiophen-2- ylmethyl]indol-1-yl}acetic acid, {5-fluoro-2-methyl-3-[3-methyl-5-(pyridine-2-sulfonyl)-3H-imidazol-4- ylmethyl]indol-1-yl}acetic acid, {5-fluoro-3-[2-(3-fluorophenylsulfamoyl)pyridin-3-ylmethyl]-2-methylindol-1- yl}acetic acid, [3-(4-benzenesulfonyloxazol-5-ylmethyl)-5-fluoro-2-methylindol-1- yl]acetic acid, {3-[2-(3-cyanophenylsulfamoyl)benzyl]-5-fluoro-2-methylindol-1-yl}acetic acid, [3-(4-benzenesulfonylthiazol-5-ylmethyl)-5-chloro-2-methyl-indol-1-yl]acetic acid, [3-(4-benzenesulfonyl-2-methylthiazol-5-ylmethyl)-5-fluoro-2-methylindol-1- yl]acetic acid, and [3-(4-benzenesulfonyl-3-methylisothiazol-5-ylmethyl)-5-fluoro-2- methylindol-1-yl]acetic acid.
    • 以下化合物是可用于治疗呼吸系统疾病的CRTH2拮抗剂:{3- [3-氯-4-(吡啶-2-磺酰基)异噻唑-5-基甲基] -5-氟-2-甲基吲哚-1-基} 乙酸,[3-(5-苯磺酰基-3-甲基-3H-咪唑-4-基甲基)-5-氟-2-甲基吲哚-1-基]乙酸[3-(5-苯磺酰基恶唑-4-基甲基 )-5-氟-2-甲基吲哚-1-基]乙酸,[3-(3-苯磺酰基-4-甲基噻吩-2-基甲基)-5-氟-2-甲基吲哚-1-基]乙酸, {5-氟-2-甲基-3- [2-(吡啶-2-基氨磺酰基)苄基]吲哚-1-基}乙酸{5-氟-2-甲基-3- [4-甲基-3- (吡啶-2-磺酰基)噻吩-2-基甲基]吲哚-1-基}乙酸{5-氟-2-甲基-3- [3-甲基-5-(吡啶-2-磺酰基) 咪唑-4-基甲基]吲哚-1-基}乙酸,{5-氟-3- [2-(3-氟苯基氨磺酰基)吡啶-3-基甲基] -2-甲基吲哚-1-基}乙酸[3 - (4-苯磺酰氧基-5-基甲基)-5-氟-2-甲基吲哚-1-基]乙酸{3- [2-(3-氰基苯基氨磺酰基)苄基] -5-氟-2-甲基吲哚-1-基] 乙酸,[3- (4-苯磺酰基噻唑-5-基甲基)-5-氯-2-甲基 - 吲哚-1-基]乙酸[3-(4-苯磺酰基-2-甲基噻唑-5-基甲基)-5-氟-2- 甲基吲哚-1-基]乙酸和[3-(4-苯磺酰基-3-甲基异噻唑-5-基甲基)-5-氟-2-甲基吲哚-1-基]乙酸。
    • 7. 发明申请
    • INDOLIZINE DERIVATIVES WITH CRTH2 RECEPTOR AFFINITY FOR THE TREATMENT OF INFLAMMATORY DISEASES
    • 具有CRTH2受体亲和力的吲哚美辛衍生物用于治疗炎症性疾病
    • WO2009044134A1
    • 2009-04-09
    • PCT/GB2008/003328
    • 2008-10-02
    • ARGENTA DISCOVERY LIMITEDHYND, GeorgeMONTANA, John, GaryFINCH, Harry
    • HYND, GeorgeMONTANA, John, GaryFINCH, Harry
    • C07D471/04A61K31/437A61P11/00
    • C07D471/04
    • Compounds of formula (I) are ligands of the CRTH2 receptor useful in the treatment of, for example, inflammatory respiratory diseases: R 1 is fluoro, chloro, CN or CF 3 ; R 2 is hydrogen, fluoro or chloro; X is -CH 2 -, or - S(O) n -; Ar 1 is phenyl or 5- or 6-membered heteroaryl, wherein the phenyl or heteroaryl rings are optionally substituted with one substituent selected from fluoro, chloro, CN, -O(C 1 C 3 alkyl) or C 1 -C 3 alkyl, the latter two groups being optionally substituted by one or more fluoro atoms; Y is -CR 3 R 4 -, -C(O)-, -O-, -S(O) n - or -NR 3 -; R 3 and R 4 independently represent hydrogen or C 1 C 3 alkyl; Ar 2 is phenyl or 5- or 6- membered heteroaryl, wherein the phenyl or heteroaryl rings are optionally substituted by one or more substituents independently selected from halogen, - CN, -S(O) n R 5 , -S(O) 2 NR 6 R 7 , -NR 6 S(O) 2 R 5 -NR 6 R 7 , -NR 6 COR 5 , -CONR 6 R 7 , - COR 5 , -OR 6 , C 1 C 6 alkyl or C 3 -C 7 cycloalkyl, the latter two groups being optionally substituted by one or more fluoro atoms; R 5 is C 1 C 6 alkyl or C 3 -C 7 cycloalkyl, optionally substituted by one or more fluoro atoms; R 6 and R 7 independently represent hydrogen, C 1 C 6 alkyl or C 3 -C 7 cycloalkyl, the latter two groups being optionally substituted by one or more fluoro atoms; and n is O, 1 or 2.
    • 式(I)化合物是可用于治疗例如炎症性呼吸道疾病的CRTH2受体的配体:R 1是氟,氯,CN或CF 3; R2是氢,氟或氯; X是-CH 2 - 或-S(O)n - ; Ar1为苯基或5-或6-元杂芳基,其中苯基或杂芳基环任选被一个选自氟,氯,CN,-O(C 1 -C 3烷基)或C 1 -C 3烷基的取代基取代,后两个基团任选被 一个或多个氟原子; Y是-CR 3 R 4 - , - C(O) - , - O - , - S(O)n - 或-NR 3 - ; R3和R4独立地表示氢或C1C3烷基; Ar 2是苯基或5-或6-元杂芳基,其中苯基或杂芳基环任选地被一个或多个独立地选自卤素,-CN,-S(O)nR 5,-S(O)2 NR 6 R 7,-NR 6 S (O)2R5 -NR6R7,-NR6COR5,-CONR6R7,-COR5,-OR6,C1C6烷基或C3-C7环烷基,后两个基团任选被一个或多个氟原子取代; R5是任选被一个或多个氟原子取代的C 1 -C 6烷基或C 3 -C 7环烷基; R6和R7独立地表示氢,C1C6烷基或C3-C7环烷基,后两个基团任选被一个或多个氟原子取代; 并且n为O,1或2。
    • 10. 发明申请
    • INDOLIZINE DERIVATIVES WITH CRTH2 RECEPTOR AFFINITY FOR THE TREATMENT OF INFLAMMATORY DISEASES
    • 具有CRTH2受体亲和力的吲哚美辛衍生物用于治疗炎症性疾病
    • WO2009044147A1
    • 2009-04-09
    • PCT/GB2008/003345
    • 2008-10-02
    • ARGENTA DISCOVERY LIMITEDHYND, GeorgeMONTANA, John, GaryFINCH, HarryCRAMP, Michael, ColinGOLD, JohanCARNEVALE, Gennaro
    • HYND, GeorgeMONTANA, John, GaryFINCH, HarryCRAMP, Michael, ColinGOLD, JohanCARNEVALE, Gennaro
    • C07D471/04A61K31/437A61P11/00
    • C07D471/04
    • Compounds of formula (I) are ligands of the CRTH2 receptor, useful in the treatment of, for example, inflammatory respiratory disease: R 1 is fluoro, chloro, CN or CF 3 ; R 2 is hydrogen, fluoro or chloro; X is -CH 2 -, or - S(O) n -; Ar 1 is phenyl or 5- or 6-membered heteroaryl, wherein the phenyl or heteroaryl rings are optionally substituted with one substituent selected from fluoro, chloro, CN, -O(C 1 -C 3 alkyi) or C 1 -C 3 alkyl, the latter two groups being optionally substituted by one or more fluoro atoms; Y is -CR 3 R 4 -, -C(O)-, -O-, -S(O) 2 - or -NR 3 -; R 3 and R 4 independently represent hydrogen or C 1 -C 3 alkyl; Ar 2 is phenyl or 5- or 6- membered heteroaryl, wherein the phenyl or heteroaryl rings are optionally substituted by one or more substituents independently selected from halogen, - CN, -S(O) n R 5 , -S(O) 2 NR 6 R 7 , -NR 6 S(O) 2 R 5 -NR 6 R 7 , -NR 6 COR 5 , -CONR 6 R 7 , -COR 5 , -OR 6 , C 1 - C 6 alkyl or C 3 -C 7 cycloalkyl, the latter two groups being optionally substituted by one or more fluoro atoms; R 5 is C 1 -C 6 alkyl or C 3 -C 7 cycloalkyl, optionally substituted by one or more fluoro atoms; R 6 and R 7 independently represent hydrogen, C 1 -C 6 alkyl or C 3 -C 7 cycloalkyl, the latter two groups being optionally substituted by one or more fluoro atoms; and n is O, 1 or 2.
    • 式(I)化合物是CRTH2受体的配体,可用于治疗例如炎性呼吸系统疾病:R1是氟,氯,CN或CF3; R2是氢,氟或氯; X是-CH 2 - 或-S(O)n - ; Ar1为苯基或5-或6-元杂芳基,其中苯基或杂芳基环任选被一个选自氟,氯,CN,-O(C 1 -C 3烷基)或C 1 -C 3烷基的取代基取代,后两个基团任选 被一个或多个氟原子取代; Y是-CR 3 R 4 - , - C(O) - , - O - , - S(O)2 - 或-NR 3 - ; R3和R4独立地表示氢或C1-C3烷基; Ar 2是苯基或5-或6-元杂芳基,其中苯基或杂芳基环任选地被一个或多个独立地选自卤素,-CN,-S(O)nR 5,-S(O)2 NR 6 R 7,-NR 6 S (O)2R5 -NR6R7,-NR6COR5,-CONR6R7,-COR5,-OR6,C1- C6烷基或C3-C7环烷基,后两个基团任选被一个或多个氟原子取代; R5是任选被一个或多个氟原子取代的C 1 -C 6烷基或C 3 -C 7环烷基; R6和R7独立地表示氢,C1-C6烷基或C3-C7环烷基,后两个基团任选被一个或多个氟原子取代; 并且n为O,1或2。